Management Change/Compensation Form 8 K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 16, 2024, Petros Pharmaceuticals, Inc. (the "Company") entered into an Offer Letter Amendment (the "Amendment"), effective as of October 16, 2024 (the "Effective Date"), with Fady Boctor ("Boctor"), the Company's President and Chief Commercial Officer, for the purpose of amending that certain Employment Offer Letter, effective February 19, 2021, by and between the Company and Boctor (the "Offer Letter").

The Amendment, among other things: (i) allows Boctor to engage in other consulting or employment activities for direct or indirect remuneration, so long as such engagement or service does not create a conflict of interest with, or interfere with the performance of, his duties under the Offer Letter or conflict with any covenants with the Company; (ii) amends the term of the Offer Letter, which shall terminate on December 31, 2024; and (iii) adjusts Boctor's base salary from an annual rate of $350,000 to an annual rate of $280,000 effective as of the Effective Date.

Except as expressly amended by the Amendment, the Offer Letter remains in full force and effect in accordance with the provisions thereof.

The foregoing description of the material terms of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of such amendment, which is filed as Exhibit 10.1 hereto and incorporated by reference herein.